Pharmacologic and pharmacokinetic profile of mibefradil, a T- and L- type calcium channel antagonist

Darrell R. Abernethy

Research output: Contribution to journalArticle


Mibefradil is a recently introduced calcium antagonist that, as a tetralol derivative, is chemically distinct from previous calcium antagonists. This article will review pertinent results from in vitro, animal, and clinical investigations to report the pharmacologic properties that distinguish mibefradil from all of the calcium channel antagonists in use today, all of which operate on the 'L-type' calcium channel. Mibefradil's pharmacokinetic profile indicates it can be used as a once-daily oral treatment for hypertension and chronic stable angina pectoris.

Original languageEnglish (US)
JournalThe American Journal of Cardiology
Issue number4 B
Publication statusPublished - Aug 21 1997
Externally publishedYes


ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this